Bradykinin and The Firazyr MOA

FIRAZYR is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Increased bradykinin levels trigger symptoms of an HAE attack1,2

Most patients with HAE have an underlying deficiency of functional C1 esterase inhibitor that leads to an increase in plasma kallikrein activity, triggering an overproduction of bradykinin. This causes an increase in blood vessel permeability, which allows fluid to pass through the blood vessel walls causing subcutaneous or submucosal swelling.

FIRAZYR is a proven bradykinin B2-receptor antagonist used to treat HAE attacks3

FIRAZYR inhibits bradykinin from binding to the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE

Illustration of the pathway leading to a generation of bradykinin. Patients with HAE have an underlying deficiency in functional C1-INH that leads to an overproduction of bradykinin.

Adapted from Zuraw 2008 and Kaplan 2010.4,5

  1. Bradykinin binding to the B2 receptor
  2. FIRAZYR inhibiting bradykinin from binding to the B2 receptor